Urogen Pharma's (URGN) Zusduri treatment was approved by the US Food and Drug Administration for the treatment of adult patients with a type of bladder cancer, the agency said Thursday.
The regulator said the medicine was approved as a treatment of recurrent low-grade intermediate-risk non-muscle invasive bladder cancer.
Last month, the FDA's Oncologic Drugs Advisory Committee narrowly voted against the medicine's approval.
The FDA's decision was based on a single-arm, multicenter trial in 240 adults. Of the 223 patients evaluable for response, 78% had a complete response, a measure of how well a cancer drug works, the FDA said.
Shares were halted earlier and have yet to resume trading.
Price: 7.17, Change: -0.13, Percent Change: -1.78
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.